<?xml version="1.0" ?>
<document id="f2fcc16391f946c99717b63ec9a24e5384aac381">
  <chunk id="f2fcc16391f946c99717b63ec9a24e5384aac381.c0" text="Improved Pharmacological and Structural Properties of HIV Fusion Inhibitor AP3 over Enfuvirtide: Highlighting Advantages of Artificial Peptide Strategy OPEN">
    <entity charOffset="54-74" id="f2fcc16391f946c99717b63ec9a24e5384aac381.c0.e0" ontology_id="CHEBI_59886" text="HIV Fusion Inhibitor" type="chemical"/>
    <entity charOffset="65-74" id="f2fcc16391f946c99717b63ec9a24e5384aac381.c0.e1" ontology_id="CHEBI_35222" text="Inhibitor" type="chemical"/>
    <entity charOffset="135-142" id="f2fcc16391f946c99717b63ec9a24e5384aac381.c0.e2" ontology_id="CHEBI_16670" text="Peptide" type="chemical"/>
  </chunk>
  <chunk id="f2fcc16391f946c99717b63ec9a24e5384aac381.c1" text="because of short half-life, drug resistance and cross-reactivity with the preexisting antibodies in HIV-infected patients. Using an artificial peptide strategy, we designed a peptide with non-native protein sequence, AP3, which exhibited potent antiviral activity against a broad spectrum of HIV-1 strains, including those resistant to T20, and had remarkably longer in vivo half-life than T20. While the preexisting antibodies in HIV-infected patients significantly suppressed T20's antiviral activity, these antibodies neither recognized AP3, nor attenuated its anti-HIV-1 activity. Structurally different from T20, AP3 could fold into single-helix and interact with gp41 NHR. The two residues, Met and Thr, at the N-terminus of AP3 form a hook-like structure to stabilize interaction between AP3 and NHR helices. Therefore, AP3 has potential for further development as a new HIV fusion inhibitor with improved antiviral efficacy, resistance profile and pharmacological properties over enfuvirtide.">
    <entity charOffset="28-32" id="f2fcc16391f946c99717b63ec9a24e5384aac381.c1.e0" ontology_id="CHEBI_23888" text="drug" type="chemical"/>
    <entity charOffset="143-150" id="f2fcc16391f946c99717b63ec9a24e5384aac381.c1.e1" ontology_id="CHEBI_16670" text="peptide" type="chemical"/>
    <entity charOffset="175-182" id="f2fcc16391f946c99717b63ec9a24e5384aac381.c1.e2" ontology_id="CHEBI_16670" text="peptide" type="chemical"/>
    <entity charOffset="199-206" id="f2fcc16391f946c99717b63ec9a24e5384aac381.c1.e3" ontology_id="CHEBI_16541" text="protein" type="chemical"/>
    <entity charOffset="245-254" id="f2fcc16391f946c99717b63ec9a24e5384aac381.c1.e4" ontology_id="CHEBI_22587" text="antiviral" type="chemical"/>
    <entity charOffset="484-493" id="f2fcc16391f946c99717b63ec9a24e5384aac381.c1.e5" ontology_id="CHEBI_22587" text="antiviral" type="chemical"/>
    <entity charOffset="697-700" id="f2fcc16391f946c99717b63ec9a24e5384aac381.c1.e6" ontology_id="CHEBI_16044" text="Met" type="chemical"/>
    <entity charOffset="697-700" id="f2fcc16391f946c99717b63ec9a24e5384aac381.c1.e7" ontology_id="CHEBI_16811" text="Met" type="chemical"/>
    <entity charOffset="705-709" id="f2fcc16391f946c99717b63ec9a24e5384aac381.c1.e8" ontology_id="CHEBI_16857" text="Thr," type="chemical"/>
    <entity charOffset="878-898" id="f2fcc16391f946c99717b63ec9a24e5384aac381.c1.e9" ontology_id="CHEBI_59886" text="HIV fusion inhibitor" type="chemical"/>
    <entity charOffset="889-898" id="f2fcc16391f946c99717b63ec9a24e5384aac381.c1.e10" ontology_id="CHEBI_35222" text="inhibitor" type="chemical"/>
    <entity charOffset="913-922" id="f2fcc16391f946c99717b63ec9a24e5384aac381.c1.e11" ontology_id="CHEBI_22587" text="antiviral" type="chemical"/>
  </chunk>
  <chunk id="f2fcc16391f946c99717b63ec9a24e5384aac381.c2" text="The envelope glycoprotein (Env) of the human immunodeficiency virus type 1 (HIV-1) includes the gp120 surface subunit and the gp41 transmembrane subunit. As a class I transmembrane protein, gp41 plays a significant role in the membrane fusion and virus entry of HIV-1 1,2 . After the binding of the gp120 to the cellular receptors, gp41 undergoes conformation changes after fusion peptide (FP) inserts into the">
    <entity charOffset="13-25" id="f2fcc16391f946c99717b63ec9a24e5384aac381.c2.e0" ontology_id="CHEBI_17089" text="glycoprotein" type="chemical"/>
    <entity charOffset="215-219" id="f2fcc16391f946c99717b63ec9a24e5384aac381.c2.e1" ontology_id="CHEBI_50906" text="role" type="chemical"/>
    <entity charOffset="381-388" id="f2fcc16391f946c99717b63ec9a24e5384aac381.c2.e2" ontology_id="CHEBI_16670" text="peptide" type="chemical"/>
  </chunk>
</document>
